Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts by Zeribe C. Nwosu et al.
REVIEW
published: 01 June 2016
doi: 10.3389/fphys.2016.00191
Frontiers in Physiology | www.frontiersin.org 1 June 2016 | Volume 7 | Article 191
Edited by:
Jiri Kanta,
Charles University Faculty of Medicine
Hradec Kralove, Czech Republic
Reviewed by:
Matthias J. Bahr,
Sana Kliniken Lübeck, Germany
Wing-Kin Syn,
The Institute of Hepatology,
Foundation for Liver Research, UK
*Correspondence:
Steven Dooley
steven.dooley@medma.
uni-heidelberg.de
†
Present Address:
Yan Liu,
Boehringer Ingelheim Pharma GmbH
& Co.KG, Biberach, Germany
Specialty section:
This article was submitted to
Gastrointestinal Sciences,
a section of the journal
Frontiers in Physiology
Received: 30 December 2015
Accepted: 12 May 2016
Published: 01 June 2016
Citation:
Nwosu ZC, Alborzinia H, Wölfl S,
Dooley S and Liu Y (2016) Evolving
Insights on Metabolism, Autophagy,
and Epigenetics in Liver
Myofibroblasts. Front. Physiol. 7:191.
doi: 10.3389/fphys.2016.00191
Evolving Insights on Metabolism,
Autophagy, and Epigenetics in Liver
Myofibroblasts
Zeribe C. Nwosu 1, Hamed Alborzinia 2, Stefan Wölfl 2, Steven Dooley 1* and Yan Liu 1 †
1Molecular Hepatology Section, Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
Germany, 2 Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany
Liver myofibroblasts (MFB) are crucial mediators of extracellular matrix (ECM) deposition
in liver fibrosis. They arise mainly from hepatic stellate cells (HSCs) upon a process
termed “activation.” To a lesser extent, and depending on the cause of liver damage,
portal fibroblasts, mesothelial cells, and fibrocytes may also contribute to the MFB
population. Targeting MFB to reduce liver fibrosis is currently an area of intense research.
Unfortunately, a clog in the wheel of antifibrotic therapies is the fact that although MFB
are known to mediate scar formation, and participate in liver inflammatory response,
many of their molecular portraits are currently unknown. In this review, we discuss
recent understanding of MFB in health and diseases, focusing specifically on three
evolving research fields: metabolism, autophagy, and epigenetics. We have emphasized
on therapeutic prospects where applicable and mentioned techniques for use in MFB
studies. Subsequently, we highlighted uncharted territories in MFB research to help direct
future efforts aimed at bridging gaps in current knowledge.
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INTRODUCTION
Long-term exposure of the liver to injurious xenobiotic insults is a major cause of liver fibrosis
and its sequelae, notably cirrhosis, acute liver failure, and liver cancer. Fibrosis is characterized by
the net accumulation of extracellular matrix (ECM) and scar formation. This process is driven by
a heterogeneous population of liver myofibroblasts (MFB) that are recruited to and accumulate
at the site of injury. Hepatic stellate cells (HSCs) are widely accepted as the major source of liver
MFB. Studies have consistently shown that upon activation to MFB, HSCs play a crucial role in
the development of liver fibrosis. The activation process is induced by various stimulatory factors,
Abbreviations: 3PO, Cell-permeable inhibitor of PFKFB3; ACC, Acyl CoA carboxylase; ACLY, ATP citrate lyase; ALD,
Alcoholic liver disease; ADRP, Adipose differentiation-related protein; BDL, Bile duct ligation; CCl4, Carbon tetrachloride;
CTGF, Connective tissue growth factor; DHA, Docosahexaenoic acid; ECM, Extracellular matrix; FA, Fatty acid; FASN, Fatty
acid synthase complex; FDFT1, Farnesyl-diphosphate farnesyltransferase 1; GLUT1, Glucose transporter 1; GSK3β, Glycogen
synthase kinase 3 beta; H3K9me2, Histone H3 dimethyl Lys9; HCC, Hepatocellular carcinoma; HDAC, Histone deacetylase;
HK2, Hexokinase 2 (muscle isoform); HMGCR, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; HMGCS, 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 1; HSCs, Hepatic stellate cells; IL, Interleukin; LDs, Lipid droplets; LX-2, immortalized
human hepatic stellate cells; MCT4, Monocarboxylate transporter 4; MFB, Myofibroblasts; MMP, Matrix metalloproteinase;
NASH, Non-alcoholic steatohepatitis; OA, Oleic acid; PA, Palmitic acid; PPARγ, Peroxisome proliferator-activated receptor
gamma; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; PKM2, Pyruvate kinase M2 (muscle isoform);
PUFAs, Polyunsaturated fatty acids; ROS, Reactive oxygen species; TCA, Tricarboxylic acid; TGF-β, Transforming growth
factor beta; VPA, Valproic acid; α-SMA, alpha smooth muscle actin.
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including transforming growth factor beta (TGF-β) and
inflammatory cytokines (Dooley et al., 2003; Gabbiani, 2003;
Mederacke et al., 2013; Seki and Schwabe, 2015). Besides HSCs,
other cell types such as portal fibroblasts, bone marrow-derived
fibrocytes and mesothelial cells may also contribute to liver MFB
in response to chronic injury (Iwaisako et al., 2014; Xu et al.,
2015).
Regardless of their origin, MFB are highly contractile,
proliferative, and produce ECM components such as collagen
types I, III, and fibronectin (Bataller and Brenner, 2005).
MFB mediate reconstruction of connective tissues upon injury
(Gabbiani, 2003; Swiderska-Syn et al., 2014). For example,
following partial hepatectomy, MFB not only accumulate at the
site of injury to initiate liver regeneration, but also activate
liver progenitor cells, and subsequently induce proliferation of
hepatocytes and cholangiocytes via hedgehog signaling pathway
(Swiderska-Syn et al., 2014). It is therefore conceivable that
extremely sophisticated mechanisms are responsible for the
timely activation, recruitment, homing, and perpetuation ofMFB
functions at injured sites. There is also evidence that activated
HSCs may undergo a coordinated reversion to quiescence once
“their job” is done (Pellicoro et al., 2014).
In the last decade, new understanding of cellular metabolism
arose especially with regards to cancer cells. This followed
consistent in vitro and in vivo experimental proofs that
tumor cells reprogram their metabolism to ensure continual
survival (Vander Heiden et al., 2009; Hanahan and Weinberg,
2011). However, quite contrary to prevailing views, metabolic
alterations or reprogramming are not exclusive to cancer
cells. In fact, many other cell types, including dendritic cells,
macrophages, T-cells, myeloid derived suppressor cells, cortical
astrocytes, microglia, and skeletal muscle cells may also undergo
metabolic changes under a variety of initiating factors (Bentaib
et al., 2014; Gimeno-Bayón et al., 2014; Kelly and O’Neill, 2015;
Maekawa et al., 2015; Pallett et al., 2015; Ryall et al., 2015; Shi
et al., 2015; Xu et al., 2015). Hence, after years of focus on
cell signaling, it is time to refocus efforts on how metabolic
perturbations might influence the activity of MFB, including any
therapeutic prospects it holds.
Closely linked to metabolism is autophagy (Galluzzi et al.,
2014; Filomeni et al., 2015), and in many contexts, both processes
have the same goal—energy generation. In autophagy, cells “eat
up” their cellular components to produce sufficient energy to
meet other immediate needs; however, autophagy could also be a
cell death process (Elmore, 2007; Green and Levine, 2014). Such a
dynamic system could be pivotal in MFB homeostasis. Metabolic
alterations and autophagic responses may have epigenetic twists,
e.g., via the transcriptional switch of critical gene networks
(Hanley et al., 2010). Thus, epigenetic processes could enhance
or suppress gene functions as the need arises during HSC-MFB
transdifferentiation.
In this review, we have highlighted current knowledge on
metabolism, autophagy and epigenetics in liver MFB. We also
briefly mention recent technical advances that could help unravel
new insights on the three topics in discourse. Finally, we
offer perspectives to stimulate further questions on the role of
metabolism, autophagy, and epigenetics in liver MFB.
METABOLIC ALTERATIONS IN LIVER
MYOFIBROBLASTS
There is a growing knowledge of metabolic alterations in
various types of cells. Despite paucity of experimental evidences,
it is plausible that metabolic alterations are critical in the
transdifferentiation of HSCs toMFB. Key intermediarymetabolic
pathways previously implicated in malignant transformation and
cell survival, may be intricately involved in the maintenance of
membrane integrity, morphology, energy production, signaling
among other functions in MFB. Thus, metabolism could control
the balance between MFB and the reversal to quiescent HSCs
(Figure 1).
Glycolysis
The role of glycolysis in MFB origin or function is currently
understudied. HSCs gain a glycolytic phenotype upon activation
(Chen et al., 2012). Specifically, several glycolytic targets
including GLUT1, HK2, PKM2, and lactate transporter MCT4
were simultaneously upregulated with alpha smoothmuscle actin
(α-SMA) during culture activation of HSCs and in animal liver
fibrosis models (Chen et al., 2012). The glycolytic feature was
mediated via Hedgehog (Hh) signaling and strongly correlated
with expression of hypoxia inducible factor 1α (HIF1α), a known
transcriptional regulator of glycolytic genes (Chen et al., 2012).
Mechanistically, damaged hepatocytes release Hedgehog ligands,
which activate HSCs via Hh signaling mediator Smoothened
(SMO), and HIF1α induction. Deletion of SMO in quiescent
HSCs suppressed basal mRNA expression of Glut1, Hk2, Pkm2,
and HIF1α, while the opposite effect was observed with SMO
agonist (SAG). Hence, the authors confirmed a direct link
between MFB glycolytic activity and progression of liver fibrosis
since inhibition of Hh signaling, HIF1α, glycolysis, or lactate
accumulation all converted MFB to quiescent HSCs. In addition,
the number of glycolytic stromal cells, as determined by PKM2
expression, also correlated with the severity of fibrosis in diseased
livers of animals and patients (Chen et al., 2012). Consistent
with the above findings, Hh signaling inhibitors with potent
antifibrotic effects (i.e., cyclopamine and curcumin) were recently
shown to decrease intracellular levels of adenosine triphosphate
(ATP), lactate, and the expression of glycolytic targets HK,
PFK2, and Glut4 in HSCs (Lian et al., 2015). These evidences
support the role of glycolysis in HSC activation and highlight
the possibilities of targeting this metabolic pathway toward
ameliorating fibrosis. Obviously, more studies are required to
investigate the direct effect of modulating glycolytic targets
in HSCs. Specifically, findings from MFB of other cellular
origin could be tested in liver MFB. For example, glycolytic
alterations are observed during MFB differentiation in the
lung and prostate. Lung MFB at their early activation stage
have increased and sustained expression of glycolytic enzymes
PFK1, HK2, and notably PFKFB3. Inhibition of PFKFB3 with
3PO suppressed fibroblast differentiation to MFB (Xie et al.,
2015). In the prostate, however, TGF-β1-induced fibroblast-to-
MFB transdifferentiation led to suppression of pyruvate kinase,
PKM2 (Untergasser et al., 2005). In cancer-associated fibroblasts,
the glycolytic product lactate is associated with increased
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FIGURE 1 | A schematic model of metabolism, autophagy, and epigenetics in HSC-to-MFB transdifferentiation based on evolving research insights. In
this model, quiescent HSC exposed to various stimuli transdifferentiate to activated HSC (MFB) and loose lipid droplets (LDs). Prior to or during transdifferentiation,
transcription-level alterations modulate the expression of relevant metabolic, autophagy, and epigenetic mediators (?). Epigenetic modifiers (e.g., HDACs, DNMTs,
MECP2, etc.) may determine, which transcriptional networks are switched on or off. In the transdifferentiated state, increased glycolysis, pentose phosphate pathway
(PPP), and antioxidant system as well as loss of LDs could synergize to sustain energy production (Hernández-Gea et al., 2012) and provide the metabolite pool for
extracellular matrix (ECM) and collagen synthesis (?). In the activated state, MFB may rely on nutrients from accelerated de novo metabolism, microenvironment, or
autophagic breakdown of organelles to sustain their function in fibrosis and inflammation, e.g., cytokine production. Microenvironmental factors may signal the end of
healing by (a) activating antifibrotic epigenetic modifiers, (b) attenuating transcriptional activators of metabolism and autophagy, or (c) by inducing self-destructive
autophagy in MFB (?). LPS, lipopolysaccharides; ?, unknown mechanisms.
stemness, and constitutive TGF-β receptor activation led to
metabolic reprogramming with increased lactate production
(Martinez-Outschoorn et al., 2011; Guido et al., 2012). This
suggests that lactate may be crucial in TGF-β-mediated HSC
activation. In line, baboon liver MFB treated with lactate
had an increased intracellular proline pool and upregulated
collagen synthesis (Savolainen et al., 1984). Since MFB produce
high amount of collagen (Bataller and Brenner, 2005), it will
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be interesting to test whether glucose-derived lactate could
modulate human or murine liver MFB, including analysis on
the role of lactate dehydrogenases in this context. Together,
the currently available information suggests that glycolysis
is critical in MFB physiology and offers hints for further
investigations.
Tricarboxylic Acid (TCA) Cycle
The role of TCA in HSC activation or MFB function is still
unclear and the relevance of most TCA enzymes is yet to be
delineated. It is also unclear if loss of lipid droplets (LDs),
which occurs during HSC activation (Blaner et al., 2009; Kluwe
et al., 2011), is aimed at supplying acetyl-CoA for TCA via
β-oxidation. The sole evidence of TCA involvement in HSC
activation stems from a recent study showing that succinate
induces G protein-coupled receptor 91 (GPR91) to increase
the production of TGF-β, collagen type I, and α-SMA (Li
et al., 2015). This link between succinate and HSC activation
suggests a likely relevance of TCA intermediates in metabolism
and signaling regulation during HSC-MFB transdifferentiation.
Noteworthy, succinate level is significantly increased in lung
MFB and fibrotic lungs. Succinate accumulation enhanced
TGF-β1-induced HIF-1α stabilization and MFB differentiation
(Xie et al., 2015). Thus, it will be interesting to further
investigate the effect of other TCA intermediates, including α-
ketoglutarate that was recently shown to maintain pluripotency
in embryonic stem cells via epigenetic control (Carey et al.,
2015). Other interesting intermediates are fumarate and 2-
hydroxyglutarate, which are called “oncometabolites” due to
their oncogenic effect on rapidly proliferating cells (Xu et al.,
2011; Sullivan et al., 2013; Nowicki and Gottlieb, 2015).
Whether these “oncometabolites” exert profibrotic effects on
MFB is yet to be explored. On a broader perspective,
any abnormal accumulation of TCA intermediates may alter
transcriptomic or signaling networks to initiate or sustain MFB
phenotype.
Glutamine Metabolism
Glutamine is a very abundant amino acid and a highly energy-
rich metabolite in humans. Research on mechanisms of cellular
glutamine flux have rapidly evolved in recent years to elucidate
its relevance in cell metabolism—e.g., in sustaining nucleotide
biosynthesis, TCA, and lipogenesis (DeBerardinis et al., 2007;
Metallo et al., 2012; Mullen et al., 2012; Son et al., 2013). In
HSCs, the mechanism of glutamine utilization or its relevance
to activation is currently unknown. Nevertheless, activated HSCs
are long known to express high glutamine synthetase (GS; Bode
et al., 1998). GS expression and glutamine metabolism have been
severally linked to theWnt/β-catenin signaling pathway (Cadoret
et al., 2002; Austinat et al., 2008; Schmidt et al., 2011; Karner et al.,
2015). Thus, the evidence that activation of the Wnt pathway
elevates GS expression, while suppressing HSC activation marker
α-SMA (Kordes et al., 2008) suggests that Wnt may control
HSC fate by modulating glutamine metabolism. However, since
the authors measured neither the intracellular nor extracellular
glutamine level in their experiment, it is hard to discuss the effect
of the elevated GS on glutamine metabolism. Therefore, further
studies are needed to clarify the role of glutamine in activation
and MFB bioenergetics, including any prospects of targeting
glutamine utilization in MFB.
Fatty Acid Metabolism
Fatty acids (FA) are important in liver physiology, notably
in the maintenance of membrane integrity, signaling, energy
production, and regulation of inflammation in various cellular
and tissue compartments (Freigang et al., 2013; Bazinet and Layé,
2014; Serhan, 2014). When deregulated, FA metabolism accounts
for several liver diseases such as hepatic steatosis, steatohepatitis,
and cirrhosis (Rinella, 2015). Specifically, polyunsaturated fatty
acids (PUFAs) as substrates for the cyclooxygenase pathway
vitally regulate initiation and resolution of inflammation
(Alhouayek and Muccioli, 2014; Buckley et al., 2014), and have
been linked to HSC activation. Rat HSCs at early activation stage
replace retinyl esters with PUFAs in LDs (Testerink et al., 2012).
However, the mechanism by which the incorporated PUFAs
later contribute to HSC activation is not yet known, especially
given that HSCs loose LDs during activation (Blaner et al.,
2009).
Saturated FA such as oleic acid (OA) and palmitic acids (PA)
also participate in MFB activity (Lee et al., 2010, 2014). Further,
palmitate and retinol supplementation suppress activation of
human immortalized LX-2 (Xu et al., 2005) and primary human
HSCs (Lee et al., 2010). Lee et al. found that palmitate and
retinol induced adipose differentiation-related protein (ADRP),
which regulates the formation of LDs. Mechanistically, ADRP
induction led to LDs formation, and the suppression of activation
and fibrogenic targets including α-SMA, collagen, and MMP1
(Lee et al., 2010). The effect of OA and PA on increasing lipid
storage was also corroborated by a recent study, in which these
FA were reported to further synergize with natural compounds,
such as rutin and curcumin, to increase LDs and suppress
proliferation of HSCs (Lee et al., 2014). On the contrary,
OA treatment induced TGF-β, which ostensibly promoted the
MFB phenotype in mesangial cells by inducing the expression
of collagen I, fibronectin,and α-SMA (Mishra and Simonson,
2008); whether OA similarly induces TGF-β in HSCs is yet
unknown. Besides activating MFB, lipids may participate in
MFB-mediated inflammatory functions. For instance, human
liver MFB were found to trigger activation of monocytes
by secreting prostaglandin-E2 (PGE2) in vitro. Accordingly,
blocking PGE2 production with cyclooxygenase 2 inhibitor (NS-
398) reduced the expression of the monocyte marker CD163
(Zhang et al., 2014).
Evidences also suggest that FA regulates MFB activation
and function in other tissues. For instance, arachidonic
acid and docosahexaenoic acid (DHA) reversed the MFB
phenotype of valvular interstitial cells from porcine aortic
valves by decreasing contractility and expression of α-SMA via
a mechanism involving suppression of RhoA/G-actin/MRTF
signaling (Witt et al., 2014). In the prostate, DHA also
suppressed fibroblast to MFB differentiation. Specifically DHA
prevented TGF-β-induced differentiation, α-SMA expression,
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and migration of prostate associated fibroblasts (Bianchini et al.,
2012). Furthermore, DHA suppressed matrix metalloproteinase
2 (MMP2) release and reversed the myofibroblast phenotype
of prostate adenocarcinoma-associated fibroblasts (Bianchini
et al., 2012). In other studies, dietary supplementation with fish
oil blocked cardiac fibroblast activation and prevented cardiac
fibrosis. Accordingly, eicosapentaenoic acid and DHA increased
cyclic GMP levels, attenuated cardiac fibroblast transformation,
proliferation, and collagen synthesis, and also blunted TGF-
β1-induced phospho-Smad2/3 nuclear translocation through
activation of cyclic GMP/protein kinase G pathway (Chen
et al., 2011). Nitrated fatty acids (NFAs), formed when nitric
oxide (NO) and NO-derived species react with unsaturated
FA, are critical mediators of signaling and inflammation-related
functions (reviewed by Trostchansky and Rubbo, 2008). NFAs
upregulated PPARγ and blocked TGF-β signaling/activity in
human lung fibroblasts (Reddy et al., 2014). In vivo, NFA
treatment led to reduction of disease severity and reversal of
existing MFB numbers and collagen deposition in a mouse
model of pulmonary fibrosis (Reddy et al., 2014). Furthermore,
resolvins, a family of lipid mediators derived from omega-3
PUFA, and known to have anti-inflammatory potency (Xu et al.,
2010), inhibited interstitial fibrosis by blocking proliferation of
resident fibroblasts (Qu et al., 2012). Despite these evidences
that fatty acids influence the MFB phenotype, no study has
directly interrogated the role of key enzymes in fatty acid
metabolism, including FASN, ACLY, ACC in HSC activation.
Hence, further studies will help to resolve the exact molecular
regulation and relevance of fatty acid metabolism in HSC
biology.
Cholesterol Metabolism
Recently, it was shown that cholesterol accumulation drives
liver fibrosis (Tomita et al., 2014). According to the authors,
increased cholesterol intake in a model of non-alcoholic
steatohepatitis (NASH) led to free cholesterol accumulation in
HSCs. Cholesterol accumulation consequently sensitized HSCs
to TGF-β-induced activation by upregulating toll-like receptor 4
protein (TLR4), which suppressed TGF-β pseudoreceptor Bambi
(Tomita et al., 2014). Similarly, in hypercholesterolemic mice
with aortic valve disease, rapid normalization of cholesterol
levels by genetic switching led to normalized superoxide levels,
decreased myofibroblast activation, and a suppressed disease
progression (Miller et al., 2009). The molecular mechanism
by which cholesterol mediates activation and fibrosis is not
fully understood. However, blocking cholesterol metabolism has
offered prospects in ameliorating MFB-mediated fibrogenesis
(Table 1).
Statins are known blockers of cholesterol metabolism
and act by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR). HMGCR catalyzes the rate-limiting step
in cholesterol metabolism (i.e., HMG-CoA → mevalonate),
which commits acetyl-CoA to cholesterol production (Sirtori,
2014). Compelling evidences suggest that commonly used
statins, such as simvastatin, pravastatin, fluvastatins, and
atorvastatin are beneficial in targeting fibrogenesis. For instance,
simvastatin suppressed HSC activation and liver fibrosis by
increasing endothelial nitric oxide synthase expression, while
suppressing the expression of inducible nitric oxide synthase
(Wang et al., 2013)—a proinflammatory mediator (Brenner
et al., 2013). Simvastatin also suppressed rat HSC proliferation
and collagen I production, and reversed the morphology of
activated HSCs toward quiescence (Rombouts et al., 2003).
Further, pravastatin in combination with protein kinase c (PKC)
inhibitor (enzastaurin) yielded a synergistic antifibrotic effect
in in vitro and in vivo liver fibrosis models, notably by inducing
cell apoptosis (Yang et al., 2010). Fluvastatin was recently
shown to suppress palmitate-induced HSC activation in vitro.
In addition, fluvastatin suppressed inflammation and oxidative
stress to ameliorate steatosis-induced HSC activation and
hepatic fibrogenesis in in vivo NASH model (Chong et al., 2015).
Recently, Trebicka et al. (2010) investigated the antifibrotic
effect of atorvastatin in rats after bile duct ligation (BDL).
In their study, early (prophylactic) therapy with atorvastatin
significantly reduced fibrosis and HSC activation. On the
contrary, late atorvastatin therapy (against severe fibrosis)
transduced HSCs into a more quiescent state, and led to
suppression of MMP2 and profibrotic targets (e.g., TGF-β1,
CTGF, and PDGFβ-R), but without affecting inflammation
and fibrosis (Trebicka et al., 2010). In addition to suppressing
activation, atorvastatin also induced senescence in MFB, both
in vitro and in vivo as determined by p21 expression and
β-galactosidase staining (Klein et al., 2012). Together, these
evidences show that cholesterol-lowering agents have antifibrotic
potency. It is noteworthy that the regulatory mechanisms linking
statins to MFB deactivation are still vaguely defined. Studies
suggest that besides inhibiting cholesterol metabolism, statins
may suppress activation by attenuating membrane Ras and
cytosolic RhoA levels (Rombouts et al., 2003; Porter et al.,
2004). Statins may also mediate their antifibrotic effects by
activating the transcription factor Kruppel-like factor 2 (KLF2;
Marrone et al., 2013, 2015). In addition, the findings that
atorvastatin exerted divergent effects depending on timing of
therapy (Trebicka et al., 2010) suggest that the stage of fibrosis
may determine the mechanism of action or effects of statins on
MFB.
Besides inhibition of HMGCR, reduction of cholesterol levels
by other mechanisms may also be of therapeutic benefits in
limiting fibrogenesis. For instance, ezetimibe, which inhibits
cholesterol absorption, was found to improve hepatic fibrosis
in a controlled trial of 80 non-alcoholic fatty liver disease
patients (Takeshita et al., 2014). Noteworthy, many targets
in carnithine metabolism/transport and steroid biosynthesis,
including CPT1A, CPT1B, SQLE, SREBF, SC5DL, and HMGCS1
were deregulated in this patient cohort. However, despite
genomic evidence of suppressed HSC to MFB transition,
patients treated with ezetimibe had adverse effects, including
increased long-chain fatty acid and glycated hemoglobin
(HbA1c), which led to premature termination of the study
(Takeshita et al., 2014). It remains to be elucidated how the
cholesterol biosynthetic pathway modulates MFB features, and
no study has yet reported the role of cholesterogenic targets
like HMGCS, HMGCR, and FDFT1 in HSC activation and MFB
function.
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TABLE 1 | Summary of selected research findings on liver myofibroblast metabolism, autophagy. and epigenetics with notes on evidence of therapeutic
prospects.
Molecular process Findings/Evidence Models 1Evidence of therapeutic
prospects with inhibitor (s)?
References
Glycolysis • ↑Glycolytic phenotype and targets (GLUT1,
HK2, PKM2) during HSC differentiation
↑Number of glycolytic stromal cells
1◦ mouse HSCs (in vitro)
MCD (in vivo)
BDL (in vivo)
Yes—with 2-deoxy glucose Chen et al., 2012
• Hedgehog inhibitors suppress activation and
also lactate output and glycolytic targets (e.g.,
HK, PFK2, and Glut4)
1◦ rat HSCs (in vitro)
CCl4-induced rat fibrosis
liver (in vivo)
No Lian et al., 2015
TCA/Glutamine
metabolism
• Succinate treatment increases α-SMA via
GPR91 activation
LX-2 and 1◦ mouse HSCs
cultured in MCD (in vitro)
No Li et al., 2015
• Stimulation of β-catenin-dependent Wnt
signaling prevents HSC activation
1◦ rat HSCs (in vitro) Yes—with GSK3β inhibitor
TWS119
Kordes et al., 2008
• ↑Glutamine synthetase (GS) in activated HSCs
GS as potential marker of HSC activation
1◦ rat HSCs (in vitro) No Bode et al., 1998
Fatty
acid/Cholesterol
metabolism
• HSCs replace retinyl esters with PUFAs in lipid
droplets during activation process
↑Incorporation of exogenous arachidonic acid
1◦ rat HSCs (in vitro) No Testerink et al., 2012
• Palmitate suppress activation by ↑ADRP LX-2 and human 1◦ HSCs
(in vitro)
No Lee et al., 2010
• ↑Accumulation of oleic and palmitic acids
increases autophagy in activated HSCs
LX-2 (in vitro) No Lee et al., 2014
• Simvastatin—↓HSC proliferation, ↓collagen I,
revert HSCs to quiescence
1◦ rat HSCs (in vitro) Yes—with Simvastatin Rombouts et al., 2003
• Fluvastatin—↓palmitate-induced HSC
activation; alleviated steatosis-induced HSC
activation; ↓hepatic fibrogenesis
Rat immortalized HSCs (T6
cells; in vitro)
NASH (in vivo)
Yes—with Fluvastatin Chong et al., 2015
• Atorvastatin attenuates HSC activation and
fibrosis
BDL mice (in vivo) Yes—with Atorvastatin Trebicka et al., 2010
• Inflammatory and profibrotic function and effect
of leptin was blocked by inhibition of NADPH
oxidase
1◦ human and mouse HSCs
(in vitro)
Yes—with NADPH oxidase
inhibitor diphenylene-iodonium
(DPI)
De Minicis et al., 2008
Autophagy • Autophagy promotes fibrogenesis
Blocking autophagy via Atg7 suppress liver
fibrosis
1◦ mouse and human HSCs
Mouse immortalized HSCs
(JS1; in vitro)
Atg7 transgenic mice
(in vivo)
CCl4 and TAA-treated mice
(in vivo)
Yes—with 3-Methyladenine
(3-MA)
Hernández-Gea et al.,
2012
• Inhibition of autophagy suppress HSC
activation
1◦ mouse HSCs (in vitro) Yes—with Bafilomycine A1 Thoen et al., 2011
Epigenetics • JMJD1A—novel epigenetic regulator in HSCs
↓JMJD1A correlates with reinforced H3K9me2
in the PPARγ gene promoter, ↑α-SMA and
collagen
CCl4-treated mice
(in vivo)
No Jiang et al., 2015
• Epigenetic silencing of Smad7 enables
TGF-β1-induced fibrosis via Smad2/3
Rat HSCs (in vitro) Yes—with
5-aza-2’-deoxycytidine
(5-azadC)
Bian et al., 2014
• Ethanol induce multiple epigenetic regulators,
including a histone 3 lysine 4 (H3K4)
methyltransferase (MLL1) during HSC
activation
1◦ rat HSCs (in vitro) No Page et al., 2015
• VDR ligands inhibit TGF-β1-induced HSC
activation by blocking recruitment of histone
modifiers (CBP and p300) and histone H3
hyperacetylation in profibrotic genes
*LX-2 cells
1◦ rat and mouse HSCs
Vdr−/− mice (in vivo)
CCl4-treated mice (in vivo)
Yes—with Vit-D agonist
Calcipotriol
Ding et al., 2013
(Continued)
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TABLE 1 | Continued
Molecular process Findings/Evidence Models 1Evidence of therapeutic
prospects with inhibitor (s)?
References
• MRTF-A mediates fibrosis by recruiting histone
methyltransferase complex to the promoters of
fibrogenic genes to activate transcription
1◦ mouse HSCs (in vitro)
HSC-T6 cells (in vitro)
MRTF-A KO
mice treated with CCl4
(in vivo)
No Tian et al., 2015
• HDAC inhibition blocks activation markers
α-SMA, lysyl oxidase, collagens.
1◦ mouse HSCs (in vitro)
**CCl4-treated mice (in vivo)
Yes—with HDAC class II
inhibitor, MC1568
Mannaerts et al., 2013
• HDAC inhibition blocks HSC proliferation,
activation, and suppress liver fibrosis
1◦ mouse and human HSCs
(in vitro)
BDL rat (in vivo)
Yes—with HNHA Park et al., 2014
• HDAC inhibition blocks HSC activation and
fibrosis
1◦ mouse HSCs (in vitro)
CCl4-treated mice (in vivo)
Yes—with Valproate Mannaerts et al., 2010
1Refers only to part of the study showing inhibitors that directly target a gene or pathway in the respective molecular process; 1◦, Primary; BDL, Bile duct ligation; CCl4, Carbon
tetrachloride; MCD, Methionine choline-deficient; MRTF, Myocardin-related transcription factor; NASH, Non-alcoholic steatohepatitis; TAA, Thioacetamide ↑, increase or upregulation;
KO, knockout; ↓, decrease or downregulation; HNHA, N-hydroxy-7-(2-naphthylthio)heptanomide; *The main model used to demonstrate the antagonistic role of VDR ligand on
TGFβ1-induced activation; **In vivo data was inconclusive due to variabilities within samples (Mannaerts et al., 2013).
Oxidative Stress and Anti-oxidant Defense
System
Oxidative stress and the cellular anti-oxidant defense system are
regulated in a coordinated fashion during inflammation. It is
known that reactive oxygen species (ROS) such as hydrogen
peroxide and superoxides are released and scavenged during
hepatic wound healing (Prosser et al., 2006). This process must
be coordinated by a plethora of tightly regulated mechanisms
to ensure homeostatic balance. Some well-studied anti-oxidant
mediators, such as NADPH Oxidase, galectin-3, glutathione, and
superoxide dismutases are involved inMFB physiology and could
be prospective targets in fibrotic therapy.
NADPH Oxidase 4 (NOX4) is a key mediator of the cellular
antioxidant system, which is known to be upregulated in fibrosis
and linked to TGF-β fibrotic action. Targeted inhibition of NOX4
suppresses HSC activation and also the initiation or progression
of fibrogenesis in other organs including lung, breast, kidney, and
heart (Cucoranu et al., 2005; Aoyama et al., 2012; Sancho et al.,
2012; Chan et al., 2013; Hecker et al., 2014; Manickam et al., 2014;
Sampson et al., 2014; Tobar et al., 2014; Lan et al., 2015). In line,
pharmacological and genetic inhibition of NADPH oxidase in
HSCs blocked inflammatory and profibrotic functions of leptin,
e.g., enhanced HSC proliferation; up-regulation of fibrogenic
markers, inflammatory mediators, and chemokine expression,
thus supporting a role of NOX in mediating fibrogenesis via
signaling control (De Minicis et al., 2008).
Galectin-3 is a pleiotropic β-galactoside-binding lectin.
Galectin-3 associates with cell adhesion molecules to mediate
its downstream functions such as cell apoptosis, adhesion,
migration, angiogenesis, fibrosis, and inflammatory responses
(Li et al., 2014). Galectin-3 is overexpressed upon injury and
regulates hepatic progenitor cell expansion and HSC activation
(Henderson et al., 2006; Hsieh et al., 2015). In addition, several
studies show that galectin-3 expression has direct correlation
with HSC phagocytosis, matrix production, and hepatic fibrosis
(Maeda et al., 2003; Henderson et al., 2006; Jiang et al., 2012;
Martínez-Martínez et al., 2014). Recently, galectin-3 was found
to function as a scavenging receptor for advanced lipoxidation
endproducts (ALEs) in the liver. Consequently, galectin-3
deficient mice fed with atherogenic diet present with less steatosis
and reduced tissue uptake of ALEs (Iacobini et al., 2011).
Glutathione is another prominent player in the cellular
antioxidant function (Lu, 2013; Espinosa-Diez et al., 2015).
Increased glutathione suppresses HSC growth and activation (Fu
et al., 2008). Accordingly, stimulation with TGF-β suppressed
expression of glutamate-cysteine ligase (GCL), the rate-limiting
enzyme in glutathione biosynthesis, leading to lower glutathione
levels in cultured HSCs (Fu et al., 2008). This suggests that
suppression of glutathione levels is a mechanism of TGF-β-
induced fibrosis. Similarly, increased intracellular glutathione
levels in lung fibroblast inhibit Smad3 phosphorylation to
suppress TGF-β1-induced profibrotic effects, such as expression
of CTGF, collagen I, fibronectin, and transformation to MFB
(Ono et al., 2009).
Superoxide dismutase (SOD) is also suggested to have
antifibrotic activity. A study with a skin fibrosis model indicates
that exogenous Cu/Zn SOD exerts antifibrotic activity by
suppressingMFB features, such as expression of α-SMA, TGF-β1,
and ECM (Vozenin-Brotons et al., 2001). Manganese superoxide
dismutase (MnSOD) is a downstream target of the AKT-
dependent forkhead transcription factor FOXO1 (Adachi et al.,
2007). MnSOD induction via active FOXO1 partly inhibits
HSC proliferation and transdifferentiation by suppressing ROS
production (Adachi et al., 2007), further showing that anti-
oxidant mediators are crucial in HSC activation and MFB
function.
In human alcoholic hepatitis, disturbance of the antioxidant
system occurs in the background of advanced fibrosis
(Colmenero et al., 2007). Those patients present with significant
accumulation of fibrogenic MFB and overexpression of genes
involved in oxidative stress, including NOX4, as well as dual
oxidases 1 and 2. Oxidative stress is also associated with corneal
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and alveolar MFB functions (Yang et al., 2013b; Vyas-Read et al.,
2014). Furthermore, production of mitochondrial complex III
ROS is essential for TGF-β-driven MFB differentiation and
profibrotic gene expression in human lung fibroblasts (Jain
et al., 2013). However, ROS scavengers trigger TGF-β1-mediated
differentiation of human subcutaneous fibroblasts into MFB
(Cat et al., 2006; Popova et al., 2010). Taken together, oxidative
stress and anti-oxidant mediators are pivotal in activation and
MFB function. Therefore, metabolic processes that generate or
remove ROS, e.g., oxidative phosphorylation, pentose pathways,
and glutathione metabolism, may critically participate in liver
MFB activities and so represent yet untapped areas in the search
for antifibrotic therapies.
AUTOPHAGY—A PROSPECTIVE FACET IN
LIVER MYOFIBROBLASTS
PATHOPHYSIOLOGY
Autophagy, literarily meaning “self-eating,” is a rapidly emerging
facet in cellular bioenergetics. It defines a process whereby
cells eat up their cytoplasmic components in order to
generate metabolites for energy sustainability (Green and
Levine, 2014; Hurley and Schulman, 2014). In normal and
disease states, autophagy has critical survival, protective, and
immune modulatory functions—the latter including suppression
of proinflammatory cytokines (Levine et al., 2011; Choi et al.,
2013). There are several known markers of autophagy, including
the most studied ATG8/LC3, and SQSTM1/p62, ATG1/ULK1,
ATG9, and BECN1/ATG6 (Klionsky et al., 2012). However,
little and conflicting information currently exist on the role of
autophagy in HSCs, MFB, and fibrosis as discussed below.
Autophagy is Profibrotic
Recent findings implicate autophagy as promoter of liver fibrosis
(Mallat et al., 2014; Lee et al., 2015). Increased expression of
autophagy markers positively correlates with ductular reaction
(Hung et al., 2015), a process that goes hand in hand with HSC
activation in a subset of liver diseases, and thus may directly
participate in tissue repair and hepatic fibrogenesis (Williams
et al., 2014). Further, autophagy markers, notably microtubule-
associated protein 1 light chain 3B (LC3B), ATG12-5, and ATG7
were significantly upregulated in the livers of cirrhotic patients
and in 2-acetylaminofluorene (AAF)/CCl4-induced liver fibrosis
in rat (Hung et al., 2015). With LC3B as marker, the authors
showed that autophagy correlated with severity of fibrosis and
was consistently increased in cirrhosis regardless of varying
etiologies. However, while the autophagy markers correlated
with protein expression of α-SMA and bile duct proliferation
marker CK19, a direct overlap between MFB and autophagy
was not apparent in this study, as immunofluorescent staining
showed no co-localization of LC3B with α-SMA in α-SMA+
MFB (Hung et al., 2015). Considering that lipids are among
its metabolic triggers (Galluzzi et al., 2014), autophagy may
induce HSC activation by crosstalk with lipid molecules. Indeed,
autophagy facilitates loss of LDs and concomitantly promotes the
supply of free fatty acids as energy-building substrates during
HSC activation (Hernández-Gea et al., 2012). Consequently,
inhibition of autophagy with 3-Methyladenine (3-MA) decreased
ATP levels in HSCs. Furthermore, blocking autophagy by
interfering with its Atg7 attenuated CCl4 or thioacetamide-
induced liver fibrosis and matrix accumulation (Hernández-Gea
et al., 2012). The reduction of ECM accumulation and fibrosis
upon loss of autophagic function in mouse HSCs led to the
suggestion to target autophagy in fibrotic diseases (Hernández-
Gea et al., 2012). Consistent with this, earlier studies had shown
that inhibition of autophagy in cultured hepatocytes and in
mouse liver led to increased triglyceride storage and LDs (Singh
et al., 2009). Furthermore, autophagy was significantly increased
upon HSC activation, while treatment with autophagy inhibitor
Bafilomycine A1 blunted HSC activation (Thoen et al., 2011).
Treatment of rat AAF/CCl4 fibrotic model with chloroquine,
which blocks autophagic degradation in the lysosome, also
ameliorated liver injury, decreased the expression of CK19 and
pro-fibrogenic targets (COL1A1, α-SMA, TGF-β), and blunted
liver fibrosis (Hung et al., 2015). These findings suggest that
autophagy is relevant in MFB generation and is potentially
druggable toward inhibition of excessive MFB function.
Autophagy is Antifibrotic
Contrary to a direct correlation between autophagy and HSC
activation, autophagy has also been found to be protective
in fibrosis (Mallat et al., 2014). For instance, mutations in
the autophagy gene, Atg5, apparently interfered with HSC-to-
MFB transdifferentiation to protect mice against chronic CCl4-
induced liver fibrosis (Lodder et al., 2015). Atg5−/− mice treated
with CCl4 had higher hepatic levels of interleukins (IL-1A, IL-
1B), enhanced inflammatory cell recruitment, and were more
susceptible to liver fibrosis (Lodder et al., 2015). Indeed, in
studying the potential therapeutic benefits of natural compounds
in alleviating fibrosis, it was observed that activated HSCs have
increased light chain I/II (LC3 I/II) protein expression when
pre-treated with fatty acids (OA and PA) and then post-treated
with various natural compounds, including rutin and curcumin
(Lee et al., 2014). While the study confirms that FA induces
autophagy as mentioned earlier, the subsequent conclusion
that the natural compounds are potential antifibrotic agents
(Lee et al., 2014) seems to suggest that autophagy induction
(as caused by the compounds) is antifibrotic in activated
HSCs. Similarly, tonsil-derived mesenchymal stem cells could
ameliorate CCl4-induced liver fibrosis in mice via autophagy
activation, notably by reducing TGF-β and type I collagen
expression (Park et al., 2015). In pulmonary fibrosis, reduced
autophagy in aged animals also worsened the fibrotic phenotype
(Sosulski et al., 2015). In addition, TGF-β promotes lung fibrosis
by suppressing autophagy (Sosulski et al., 2015). Taken together,
autophagy may represent a highly context-dependent facet in
MFB pathophysiology. Whether autophagy is protective or
induces cell death may largely depend on the initiating factor.
Supporting this view, Rautou and colleagues argued that in most
liver diseases, autophagy is mainly protective, e.g., by allowing the
degradation of LDs in fatty acid disease and protein aggregates in
alcohol liver disease. Contrarily, Hepatitis B/C virus can subvert
autophagy for their replicative advantage (Rautou et al., 2010).
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Here, it is worthy to highlight that the loss of LDs attributed to
“protective” autophagy (Rautou et al., 2010) is also a mechanism
through which autophagy provides energy substrates to promote
HSC activation and fibrosis (Hernández-Gea et al., 2012).
Therefore, it will be of interest to further interrogate protective
and detrimental autophagy in HSC activation, MFB functions,
and in the switch between activation and dedifferentiation to
quiescence (Figure 1).
EPIGENETIC ALTERATIONS IN LIVER
MYOFIBROBLASTS
Epigenetics refer to heritable traits resulting from chromosomal
alterations that do not alter DNA sequence. Epigenetic
alterations maintain cell identity and include DNA methylation,
histone modifications, chromatin remodeling, transcriptional
control, and post-translational modification of non-coding RNA
(Berger et al., 2009; Cedar and Bergman, 2009; Portela and
Esteller, 2010; Mann, 2014). Interestingly, several epigenetic
targets, including DNA methyltransferases (DNMTs), histone
deacetylases (HDACs), histone methyltransferases (DOT1L,
EZH2, G9A), histone demethylases (JmjC-domain proteins,
LSD1), and binding domains (BET, BAZ2B, L3MBTL1) are
druggable in human diseases (Helin and Dhanak, 2013).
Epigenetic alterations occur in liver fibrosis and chronic liver
diseases (Mann, 2014; Atta, 2015; Lleo et al., 2015) and are
relevant in HSC activation (Kang et al., 2015).
DNA Methylation
During activation, HSCs accumulate methylation changes that
significantly modulate the expression of genes involved in cell
activation and inflammation (Götze et al., 2015). Specifically,
expression of DNAmethyltransferases, DNMT3A andDNMT3B,
increased with HSC activation (Götze et al., 2015). One
consequence of hypermethylation is gene silencing. For instance,
transcriptional silencing of PPARγ, which occurs during HSC
activation (Hazra et al., 2004), has been attributed to methylation
based epigenetic control (Mann et al., 2007; Yang et al.,
2012). Recently, the Jumonji Domain-Containing Protein 1A
(JMJD1A)—a histone H3K9 demethylase—was found to regulate
HSC activation and liver fibrosis by targeting PPARγ gene
expression (Jiang et al., 2015). Knockdown of JMJD1A in
HSCs correlated with reinforced H3K9me2 in the PPARγ
gene promoter; increased α-SMA and collagen expression, and
enhanced necrosis in the CCl4 mouse fibrosis model (Jiang
et al., 2015). Consistent with this finding, blocking CpG
methylation with the nucleotide analog 5-aza-2′-deoxycytidine
(5-azadC) prevented loss of PPARγ expression (Mann et al.,
2007). Methylation-based control in HSCs is also evident
from methyl-CpG-binding protein (MECP2), known to repress
chromatin structures. MECP2 is induced during HSC activation,
correlates with α-SMA expression and contributes to MFB
transdifferentiation by regulating fibrogenic targets (Mann
et al., 2007; Yang et al., 2013a). Mechanistically, MECP2
repressed Patched (PTCH1), whose loss upon hypermethylation
is necessary for sustained fibroblast activation and liver
fibrosis (Yang et al., 2013a). Furthermore, DNA methylation
is responsible for epigenetic silencing of Smad7, which
enables fibrogenic TGF-β effects via Smad2 and Smad3
phosphorylation (Bian et al., 2014). Hence, RNA interference and
5-azadC-mediated inhibition of the methylation gene DNMT1
prevented TGF-β-induced proliferation and upregulation of
activation markers in HSCs (Bian et al., 2014). More studies
are required to further validate methylation switches at
various MFB differentiation stages under normal and perturbed
microenvironments.
Histone Modification
Histone modification is another active epigenetic alteration
during HSC activation. For instance, HSCs in a mouse model
of acute liver failure secrete IL-1, which induces high MMP9
levels, leading to collagen IV degradation (Yan et al., 2008). If
uncontrolled, MMP9 expression could oppose MFB-mediated
accumulation of ECM. Hence maintenance of appropriate
balance is necessary during HSC activation or MFB function.
Interestingly, epigenetic repression of MMPs has been suggested
as a mechanism that controls HSC transdifferentiation (Qin
and Han, 2010). Consequently, MMP9 and MMP13 promoters
in MFB display impaired histone acetylation and assembly
of transcription machinery. These alterations blocked docking
of transcription factor c-Jun on the MMP promoters (Qin
and Han, 2010). Similarly, ectopic expression of HDAC4 in
quiescent HSCs suppressed intrinsic and IL-1-induced MMP
promoter activity and repressed MMP9 expression. These
findings implicate accumulation of HDACs at MMP promoters,
specifically HDAC4, as an epigenetic mechanism to repress
MMP expression during HSC activation (Qin and Han, 2010).
Similar regulation is provided via HDAC7, which represses
hepatocyte growth factor (HGF) and thus increases susceptibility
to hepatocellular damage, inflammation, and fibrosis in liver
injury (Pannem et al., 2014). HDAC7-mediated repression of
HGF in HSCs is antagonized by the tumor suppressor gene
cylindromatosis (CYLD). Accordingly, CYLD interacts with and
removes HDAC7 from the HGF promoter, hence enabling
HGF induction, which subsequently is secreted and protects
against hepatocellular injury and fibrosis (Pannem et al., 2014).
In cultured human skin fibroblasts, HDAC6, HDAC8, but
most potently HDAC4 were identified as crucial epigenetic
regulators of TGF-β-induced MFB differentiation, ostensibly
by blocking the expression of TGF-β signaling repressors 5′-
TG-3′-Interacting Factor (TGIF) and TGIF2 (Glenisson et al.,
2007).
Recently, the myocardin-related transcription factor (MRTF),
ethanol and vitamin D receptor (VDR) have been identified as
epigenomic modifiers during HSC activation. MRTF promotes
MFB differentiation, fibrosis, and TGF-β-inducedHSC activation
(Crider et al., 2011; O’Connor and Gomez, 2013; Velasquez
et al., 2013; O’Connor et al., 2015; Sisson et al., 2015).
Mechanistically, MRTF-A mediates fibrosis via recruitment of
the histone methyltransferase complex to the promoters of
fibrogenic genes and subsequent transcriptional activation (Tian
et al., 2015). Ethanol exposure was found to promote rat
HSC transdifferentiation by inducing global changes in histone
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modifying enzymes that upregulate ECM components elastin
(ELN) and collagens (Page et al., 2015). The authors found
that ethanol induced the expression of histone 3 lysine 4
(H3K4) methyltransferases, mainly MLL1. MLL1 binding was
enriched on ELN gene promoter and consequently induced
ELN expression in transitioning HSCs. In addition, MLL1
expression also correlated with ELN and collagens in ALD
liver explants further confirming that ethanol induced pro-
fibrogenic processes via epigenetic regulators (Page et al.,
2015). VDR ligands also induce chromatin remodeling as a
mechanism to counteract TGF-β-driven HSC activation (Ding
et al., 2013). TGF-β induced activation by promoting the
recruitment of histone-modifying cofactors, p300 and CBP, and
by promoting histone H3 hyperacetylation at a VDR/SMAD co-
occupied regulatory region of COL1A1. Treatment with VDR
ligands antagonized activation by disrupting TGF-β-mediated
SMAD/VDR interaction. Consequently, synthetic VDR agonist
Calcipotriol reduced collagen deposition and fibrotic gene
expression in vitro and in vivo (Ding et al., 2013). These studies
underscore the critical role of histone modification in HSC
transdifferentiation (Figure 1).
Indeed, evolving links between epigenetics and MFB function
justifies targeting histone modifiers in antifibrotic therapies.
In line, various HDAC inhibitors are effective against TGF-β-
induced MFB generation (Glenisson et al., 2007; Guo et al.,
2009; Liu et al., 2013), including MC1568, valproic acid (VPA),
trichostatin A (TSA), and butyrate. MC1568 inhibited HSC
activation markers, such as type I/III collagen, SMA, and lysyl
oxidase. In addition, MC1568 induced antifibrotic microRNA-
29 and also suppressed the proliferation of freshly isolated
mouse HSCs (Mannaerts et al., 2013). Unfortunately, the authors
were unable to reproduce the result in CCl4 fibrosis model
owing to technical issues, probably due to inefficient delivery or
fast metabolization of the drug (Mannaerts et al., 2013). VPA
also suppresses liver fibrosis and HSC activation in vitro and
in vivo (Mannaerts et al., 2010; Aher et al., 2015). However,
given the pivotal role of TGF-β in HSC activation, it is
important to mention that VPA did not interfere with early
TGF-β targets, SMAD 6 and 7 (Mannaerts et al., 2010), thus
raising further questions on the exact mechanism, by which
epigenetics influences HSC activation by TGF-β. Furthermore,
TSA and RNA interference against HDAC4 prevented MFB
differentiation as measured by α-SMA expression (Glenisson
et al., 2007). Nilotinib, a tyrosine kinase inhibitor, selectively
induces apoptotic and autophagic cell death in HSCs by
blocking HDAC 1, 2, and 4 (Shaker et al., 2013). Other HDAC
inhibitors that suppress HSC activation include a chalcone
derivative 2’,4’,6’-tris(methoxymethoxy) chalcone (TMMC; (Lee
et al., 2011)), and N-hydroxy-7-(2-naphthylthio)heptanomide
(HNHA; (Park et al., 2014)). HNHA not only suppressed HSC
proliferation, activation and liver fibrosis, but also restored
liver function and prolonged survival in the BDL rat model
(Park et al., 2014). Further evidence for targeting HDACs
in fibrotic diseases have been shown in other settings, e.g.,
cardiac and lung fibroblasts (Zhang et al., 2013; Sanders et al.,
2014; Schuetze et al., 2014). Together, these data highlight the
relevance of epigenetics in HSC activation and encourage the
exploitation of epigenetic targets in the control of MFB-mediated
fibrogenesis.
TECHNICAL ADVANCES THAT COULD
HELP DELINEATE METABOLISM,
AUTOPHAGY, AND EPIGENETICS IN LIVER
MYOFIBROBLASTS
Within the last few decades, several cutting edge techniques have
emerged for the study of complex biological processes.
In metabolism, mass spectrometry based metabolomics
techniques have been developed for measuring metabolic flux.
Consequently, it is now possible to precisely determine utility
of metabolites with a very high degree of precision (Zamboni
et al., 2009; Hiller and Metallo, 2013). Thus, metabolic flux
analyses could enable (a) holistic and simultaneous quantification
of labeled and unlabeled metabolites derived from parent carbon
sources (e.g., glucose or glutamine), (b) help to delineate the
metabolic properties of MFB at different differentiation stages,
and (c) offer hints on prospective metabolic pathways of
therapeutic relevance in HSC activation or MFB function. In
addition, cellular respiration can be easily measured by fiber
optic oxygen sensors, clark electrode, and extracellular flux
analyzers—the latter offering the advantage of assessing oxygen
consumption and extracellular acidification rates in living cells
(Zhang et al., 2012; Perry et al., 2013). Furthermore, in vivo
measurement of metabolism using hyperpolarized, (13)C-labeled
cells has been successfully applied (Rodrigues et al., 2014; Brindle,
2015). The latter in vivo approach could enhance accuracy given
the challenges of potential artifacts from cell cultures.
For autophagy studies, techniques such as time-lapse
microscopy (Muzzey and van Oudenaarden, 2009) and
transmission electron microscopy could be adopted with
molecular biology methods (Klionsky et al., 2012) to dissect
how autophagy affects the evolution of fibrosis. This could
help identify novel potential mediators of MFB autophagic
mechanisms for therapeutic purposes. Also, research on MFB
autophagy will benefit from other advances in microscopy,
e.g., super-resolution microscopy that allow high-resolution
imaging and protein tracking in living cells (Bergner et al., 2013;
Barden et al., 2015; Chéreau et al., 2015). Tools for measuring
autophagy based on biochemical features, e.g., quenching of
GFP fluorescent signals in the lysosome at low pH (Bampton
et al., 2005), could enable a more improved understanding of
autophagy during HSC transdifferention (Figure 1).
Delineating epigenetic alterations in HSCs will be
greatly enhanced by bisulfite conversion, chromatin
immunoprecipitation and high throughput DNA methylome
analyses (Shull et al., 2015; Tang et al., 2015). Other techniques,
including single cell analysis, sequencing techniques, and
multi-color fluorescence activated cell sorting could be applied
to uncover yet unknown epigenetic alterations specific to HSC
activation and MFB functions (Figure 1).
To accelerate understanding of MFB function, it is important
to consider and possibly tackle the fact that in vivo changes in
gene expression during HSC activationmay differ markedly from
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those that occur in in vitro culture (De Minicis et al., 2007). Such
differences may be due to a plethora of factors, including but not
limited to cell culture conditions, contamination by other liver
cell populations, and sample handling. Where possible, a strategy
to overcome this challenge would be to interface the assays
mentioned above with lineage tracing. Lineage tracing has been
successfully applied as a powerful innovative tool for tracking
MFB origin (Mederacke et al., 2013; Lua et al., 2014; Swiderska-
Syn et al., 2014). Hence, lineage tracing opens up the feasibility
of in vivo studies of alterations in HSCs at quiescent, transitory,
and activated states, and will highly complement genomic and
functional assays.
Finally, optimal application of novel gene editing techniques,
such as CRISPR/Cas9, TALENs, etc. (Cho et al., 2014;
Jamal et al., 2015; LaFountaine et al., 2015; Laufer and
Singh, 2015) will hugely accelerates the identification and
understanding of metabolic, autophagic, and epigenetic targets
in MFB, especially when complemented with proteomic
and transcriptomic profilings. Ultimately, perhaps the most
important technical step in understanding MFB physiology,
especially in the context of metabolism, autophagy, and
epigenetics, is to explore all possible strategies to eliminate
analytical variables that distort results.
UNCHARTED TERRITORIES IN THE
STUDY OF METABOLISM, AUTOPHAGY
AND EPIGENETICS IN LIVER
MYOFIBROBLASTS
Currently, few studies have focused on how MFB feed,
regulate survival via autophagy or via epigenetic alterations
that activate or silence key genes in spatio-temporal cell fate
decisions. Consequently, knowledge of metabolism, autophagy,
and epigenetics in MFB is still at a very nascent stage with
many convoluted parts worth further clarifications (Figure 1).
The studies that so far focused on the above subjects have offered
exciting platforms for further questions. However, more efforts
should be dedicated to delineate their molecular relevance to
MFB origin and function in health and disease. Lessons can
also be learned from other settings, e.g., cancer. For example,
metabolism has evolved as a potentially druggable process in
cancer entities and many metabolic targets are in preclinical and
clinical trials (Galluzzi et al., 2013). Whether those therapeutic
strategies would find application in MFB origin/liver fibrosis
remains an open question. It is also unknown which metabolic
priorities are exploited by MFB, e.g., particular substrates that
are indispensable for their survival. The timing of metabolic
alterations is also critical to any studies, as changes in mRNA
transcripts occur within hours in cultured HSCs (Chen et al.,
2012). Unresolved questions also abound in the area of nutrient
exchange between MFB and other liver cell populations in
the microenvironment, including the extent of their capacity
to sustain de novo anabolism. Regarding autophagy, scientific
efforts should clarify boundaries between “self-eating” autophagy
to provide energy building substrates and autophagy with a
self-destructive consequence. Questions like “how autophagy
markers contribute to MFB status” remain hugely unanswered.
Similar questions in metabolism and autophagy also apply
to epigenetics. Many epigenomic targets are druggable and
several epigenomic drugs yield a beneficial response in MFB
and fibrosis. Hence, understanding how DNA methylation
and histone modification control HSC transdifferentiation
could substantially improve the prospects of better therapeutic
interventions. Furthermore, questions also arise on possible
crosstalks or feedback loops or overarching control by potential
regulators that are chiefly responsible for MFB physiology.
These may include transcription factors, microRNAs, long non-
coding RNAs, and other regulators of the genome. Hence, it
is yet unclear under which circumstances certain regulators
switch on/off metabolism, autophagy, or epigenetic modifiers in
MFB (Figure 1). Ultimately, there are currently no established
metabolic, autophagy, or epigenetics markers in MFB. Dissecting
these uncharted territories will substantially open new windows
for therapeutic interventions in MFB-mediated fibrosis.
CONCLUSION
In the light of evolving molecular insights, metabolism,
autophagy, and epigenetics are critical players in HSC activation
and MFB functions. Currently available data lead us to propose
that transcriptional and epigenetic controls likely coordinate
metabolism and autophagy in HSC to MFB transdifferentiation
(Figure 1). In the context of the discussed molecular processes,
more studies are required to deepen understanding of MFB
origin and function in liver fibrogenesis. We suggest that ongoing
and future MFB research should interrogate the relevance of
key metabolic enzymes, autophagy markers, and epigenetic
modifiers, including but not limited to those mentioned here
and already investigated in cancer (Claus and Lübbert, 2003;
Cheong et al., 2012; Popovic and Licht, 2012; Galluzzi et al.,
2013; Helin and Dhanak, 2013; Table 1). We also recommend
that researchers should critically consider the time points
selected for MFB studies since unforeseen switch from activation
to quiescence or vice versa could obscure molecular details.
In the end, a broad-spectrum integration of cutting edge
tools that enable simultaneous measurements, such as “omics”
technologies, will enable better understanding of MFB and
further expose novel regulators or biomarkers of MFB activity.
We conclude that a detailed understanding of metabolism,
autophagy and epigenetics in liverMFBwill inspire a new frontier
in the development of antifibrotic therapy.
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